HHS Unveils Plan to Reduce Antidepressant Overprescribing After Survey Shows 17% Use

TL;DR: HHS will roll out a program to limit unnecessary antidepressant prescriptions after a 2025 survey found 17% of Americans using these drugs.

Context A nationwide survey conducted in 2025 reported that 17% of respondents were currently taking antidepressants, a class of drugs that includes selective serotonin reuptake inhibitors. The same poll showed strong opposition in every state to restricting access to these medications.

Key Facts Robert F. Kennedy Jr., the U.S. health secretary, announced the initiative at a Make America Healthy Again Institute event. He emphasized that patients will not be told to stop medication; instead, they will receive information and support to decide with their clinicians. The Department of Health and Human Services (HHS) described the effort as a push to curb psychiatric overprescribing and to promote deprescribing when clinically appropriate.

The HHS letter to providers outlines several steps: prioritize evidence‑based non‑pharmacological options such as psychotherapy, diet, exercise, and social connection; conduct thorough symptom assessments; review medication efficacy; and, when indicated, initiate deprescribing. The guidance also clarifies that clinicians can be reimbursed for the care involved in tapering patients off antidepressants and provides resources for managing the process.

The American Psychiatric Association (APA) welcomed the focus on the mental‑health crisis but warned that overprescribing is an oversimplified explanation. The APA highlighted systemic issues—workforce shortages, limited psychiatric beds, and uneven access—that also drive the crisis. It stressed that prescribing and deprescribing are routine, individualized decisions based on evidence and patient needs.

What It Means For patients, the plan means more structured conversations about the risks and benefits of continuing antidepressants. Clinicians will have new tools and reimbursement pathways to support safe tapering when a drug no longer offers clear benefit. The emphasis on non‑drug therapies may increase referrals to counseling and lifestyle programs, potentially expanding access to those services.

Policymakers will monitor prescription trends to assess whether the initiative reduces unnecessary use without compromising care quality. The APA’s call for broader system improvements suggests that deprescribing alone will not resolve the mental‑health shortage.

What to watch next: Federal reports on prescription data and early outcomes of the deprescribing program, as well as any legislative actions that could further shape mental‑health treatment standards.